Boehringer Ingelheim, Roche Partnering on New Class of Bowel Disease Therapies

Boehringer Ingelheim, Roche Partnering on New Class of Bowel Disease Therapies
Boehringer Ingelheim and Roche are teaming up to develop a new class of inflammatory bowel diseases treatments. The partners will be focusing on therapies based on an innovative approach called Locked Nucleic Acid oligonucleotide technology. Under their agreement, the companies will share the cost of developing and marketing treatments. “The opportunity to work closely with the experts at Roche to discover and develop oral, gut-targeted LNAs [Locked Nucleic Acids] for the treatment of unmet medical needs in patients suffering from IBDs is extremely motivating,” Jay Fine, global head of immunology and respiratory disease research at Boehringer Ingelheim, said in a press release. “By combining our deep knowledge of gut inflammatory diseases and immunology with Roche’s expertise in the design, development and use of LNA technology, we believe we can accelerate the delivery of novel treatments for IBD patients,” Fine said. LNAs are a class of compounds with the potential to treat a range of illnesses, including IBD. At the heart of the LNA approach is the relationship between genes, RNA and proteins. Genes are sections of DNA that produce proteins. RNA is an intermediary between DNA and genes' protein production. Abnormal genes can produce faulty RNA, which leads to abnormal proteins. LNAs' ability to target specific stretches of RNA makes them an
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *